Stevens Andrew, Milne Ruairidh, Burls Amanda
Department of Public Health and Epidemiology, Public Health Building, University of Birmingham, Edgbaston, Birmingham B15 2TT.
J Public Health Med. 2003 Jun;25(2):98-101. doi: 10.1093/pubmed/fdg022.
Health technology assessment (HTA)--the provision to decision makers of information on the value of treatments and tests--has come of age in the last two decades. But it has deep roots in health care, with notable landmarks in (1) the mid eighteenth-century development of empiricism, (2) the twentieth century interest in outcomes and variation in health care, and (3) the pioneering work of Archie Cochrane and others in the 1970s. Three main forces have driven the recent developments of HTA: a combination of concerns about the adoption of unproven technologies, rising costs, and an inexorable rise in consumer expectations. The HTA response, essentially initiatives supporting the provision of reliable synthesised research information on the effects and costs of health technologies, have been well supported in the United Kingdom and internationally. We can be sure that HTA is here to stay.
卫生技术评估(HTA)——向决策者提供有关治疗和检测价值的信息——在过去二十年中已走向成熟。但它在医疗保健领域有着深厚的根基,在以下方面有着显著的里程碑:(1)18世纪中叶经验主义的发展;(2)20世纪对医疗保健结果和差异的关注;(3)阿奇·科克伦等人在20世纪70年代的开创性工作。有三种主要力量推动了HTA的近期发展:对采用未经证实的技术的担忧、成本上升以及消费者期望的不断提高。HTA的应对措施,本质上是支持提供有关卫生技术效果和成本的可靠综合研究信息的举措,在英国和国际上都得到了有力支持。我们可以确定HTA将持续存在。